• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Klebsiella pneumoniae with carbapenemases: high prevalence of sequence type 307 with bla in South African community hospitals.产碳青霉烯酶肺炎克雷伯菌:南非社区医院中高流行的携带 bla 的序列型 307。
Eur J Clin Microbiol Infect Dis. 2024 Nov;43(11):2239-2244. doi: 10.1007/s10096-024-04947-z. Epub 2024 Sep 17.
2
Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.尿路感染分离株中的肺炎克雷伯菌碳青霉烯酶(KPC)。
Arch Microbiol. 2021 May;203(4):1825-1831. doi: 10.1007/s00203-020-02161-x. Epub 2021 Jan 28.
3
Dynamic evolution of ceftazidime-avibactam resistance from a single patient through the IncX3_NDM-5 plasmid transfer and bla mutation.从单个患者体内通过 IncX3_NDM-5 质粒转移和 bla 突变导致头孢他啶-阿维巴坦耐药性的动态演变。
Int J Antimicrob Agents. 2024 Aug;64(2):107228. doi: 10.1016/j.ijantimicag.2024.107228. Epub 2024 May 31.
4
A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring Isolated in New York City.一株耐头孢他啶-阿维巴坦、碳青霉烯类敏感的肺炎克雷伯菌的分离与鉴定:来自纽约市的报告。
mSphere. 2020 Aug 26;5(4):e00775-20. doi: 10.1128/mSphere.00775-20.
5
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
6
Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.在引入头孢他啶/阿维巴坦后,希腊 ICU 中产生碳青霉烯酶的肺炎克雷伯菌的流行情况从 blaKPC 到 blaVIM 携带株的逆转。
J Antimicrob Chemother. 2019 Jul 1;74(7):2051-2054. doi: 10.1093/jac/dkz125.
7
The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital.头孢他啶-阿维巴坦对携带不同碳青霉烯酶类型的耐碳青霉烯临床分离株在泰国大学医院的潜在应用。
Drug Des Devel Ther. 2021 Jul 16;15:3095-3104. doi: 10.2147/DDDT.S321147. eCollection 2021.
8
KPC-85, a carbapenemase-producing and ceftazidime-avibactam-resistant KPC-3 variant found in Klebsiella pneumoniae ST512 in the Netherlands.KPC-85,一种在荷兰肺炎克雷伯菌ST512中发现的产碳青霉烯酶且对头孢他啶-阿维巴坦耐药的KPC-3变体。
Int J Antimicrob Agents. 2024 Sep;64(3):107271. doi: 10.1016/j.ijantimicag.2024.107271. Epub 2024 Jul 11.
9
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
10
Changing Characteristics and Susceptibility to Ceftazidime/Avibactam of Bloodstream Extensively Drug-Resistant from a Greek Intensive Care Unit.希腊重症监护病房血流感染的广泛耐药对头孢他啶/阿维巴坦的耐药特征及敏感性变化
Microb Drug Resist. 2020 Jan;26(1):28-37. doi: 10.1089/mdr.2019.0090. Epub 2019 Aug 6.

本文引用的文献

1
The contributions of multidrug resistant clones to the success of pandemic extra-intestinal Pathogenic .多重耐药克隆对流行的肠外致病性的成功的贡献。
Expert Rev Anti Infect Ther. 2023 Apr;21(4):343-353. doi: 10.1080/14787210.2023.2184348. Epub 2023 Mar 1.
2
Molecular Genetic Epidemiology of an Emerging Antimicrobial-Resistant Clone (ST307) Obtained from Clinical Isolates in Central Panama.从巴拿马中部临床分离株中获得的一种新兴耐抗菌克隆(ST307)的分子遗传流行病学
Antibiotics (Basel). 2022 Dec 14;11(12):1817. doi: 10.3390/antibiotics11121817.
3
Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa.最佳实践:南非新型β-内酰胺/β-内酰胺酶抑制剂组合(头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦)的合理使用
S Afr J Infect Dis. 2022 Oct 20;37(1):453. doi: 10.4102/sajid.v37i1.453. eCollection 2022.
4
Molecular Mechanisms Mediating Ceftazidime/Avibactam Resistance Amongst Carbapenem-Resistant Isolates from Cancer Patients.癌症患者耐碳青霉烯类分离株中头孢他啶/阿维巴坦耐药性的分子介导机制
Infect Drug Resist. 2022 Oct 14;15:5929-5940. doi: 10.2147/IDR.S384972. eCollection 2022.
5
Treating urinary tract infections in public sector primary healthcare facilities in Cape Town, South Africa: A pharmaceutical perspective.南非开普敦公立基层医疗设施中治疗下尿路感染的药物治疗观点
S Afr Med J. 2022 Jul 1;112(7):487-493.
6
CARB-ES-19 Multicenter Study of Carbapenemase-Producing e and From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3.CARB-ES-19:一项针对来自西班牙所有省份的产碳青霉烯酶肠杆菌科细菌的多中心研究揭示了高风险克隆株如ST307/OXA-48和ST512/KPC-3的跨地区传播。
Front Microbiol. 2022 Jun 30;13:918362. doi: 10.3389/fmicb.2022.918362. eCollection 2022.
7
Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates.比较新型抗生素药物对碳青霉烯类耐药肠杆菌科临床分离株的活性。
Infect Control Hosp Epidemiol. 2023 May;44(5):762-767. doi: 10.1017/ice.2022.161. Epub 2022 Jul 13.
8
In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing : In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations.产OXA-48样酶菌株中头孢他啶/阿维巴坦耐药性的体外筛选:体外和体内适应性、遗传基础以及β-内酰胺类与新型β-内酰胺酶抑制剂或β-内酰胺增强剂联合用药的活性
Antibiotics (Basel). 2021 Oct 29;10(11):1318. doi: 10.3390/antibiotics10111318.
9
Inclusion of next-generation leaders and cost-effective precision diagnostic techniques are vital in combatting antimicrobial resistance in low- and middle-income countries.吸纳下一代领导人以及采用具有成本效益的精准诊断技术对于在低收入和中等收入国家对抗抗菌药物耐药性至关重要。
JAC Antimicrob Resist. 2020 Jun 23;2(2):dlaa032. doi: 10.1093/jacamr/dlaa032. eCollection 2020 Jun.
10
Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae isolates.碳青霉烯类耐药肺炎克雷伯菌中替加环素耐药的分子流行病学及机制。
J Clin Lab Anal. 2020 Dec;34(12):e23506. doi: 10.1002/jcla.23506. Epub 2020 Aug 20.

产碳青霉烯酶肺炎克雷伯菌:南非社区医院中高流行的携带 bla 的序列型 307。

Klebsiella pneumoniae with carbapenemases: high prevalence of sequence type 307 with bla in South African community hospitals.

机构信息

Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.

出版信息

Eur J Clin Microbiol Infect Dis. 2024 Nov;43(11):2239-2244. doi: 10.1007/s10096-024-04947-z. Epub 2024 Sep 17.

DOI:10.1007/s10096-024-04947-z
PMID:39289248
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11534848/
Abstract

This study investigated the molecular characteristics of urinary carbapenemase-producing Klebsiella pneumoniae isolates (n = 194) in Gauteng, South Africa, using simple, cost-effective PCR methodologies. Extensively drug resistant (XDR) ST307 with bla on IncX3 plasmids was endemic in Gauteng community hospitals leaving limited options for treating in- and outpatient urinary tract infections. High-level ceftazidime/avibactam resistance was detected among isolates harbouring bla including bla. These findings highlighted the need for genomic methodologies suitable for lower- and middle-income countries to track XDR clones and plasmids in community hospitals. Such results will aid with treatment and stewardship strategies.

摘要

本研究使用简单、经济有效的 PCR 方法,研究了南非豪登省产碳青霉烯酶肺炎克雷伯菌尿分离株(n=194)的分子特征。广泛耐药(XDR)ST307 型携带 bla 的 IncX3 质粒在豪登省社区医院流行,导致治疗住院和门诊尿路感染的选择有限。携带 bla 的分离株中检测到高水平头孢他啶/阿维巴坦耐药,包括 bla。这些发现强调需要适合中低收入国家的基因组方法,以追踪社区医院中的 XDR 克隆和质粒。这些结果将有助于治疗和管理策略。